Effects of L-arginine and L-lysine mixtures on splenic sympathetic nerve activity and tumor proliferation.
Oral supplementations of L-arginine and L-lysine show tumor inhibition abilities. The splenic sympathetic nerve is involved in central modulation of cellular immunity and suppresses splenic natural killer cell activity in rats. An intravenous administration of a mixture of 10 mM L-arginine and L-lysine decreased splenic sympathetic nerve activity (splenic-SNA). We examined the effect of L-arginine and L-lysine mixtures on splenic-SNA in urethane-anesthetized rats by administration of 1 ml mixtures of 2 mM, 10 mM, and 50 mM L-arginine and L-lysine. We also studied the effect of the above mixtures on human colon cancer cell proliferation in athymic nude mice. An increase in splenic-SNA and tumor volume (2 mM), no effect (10 mM), and a decrease in both values (50 mM) were seen. Bivariate correlation analysis revealed a positive correlation between changes in splenic-SNA and tumor volume, indicating the tumor suppressing ability of weakened splenic-SNA.
Shen
Jiao
J
ANBAS Corporation, 4th Floor, Nakajima Building. 4-12-17, Toyosaki, Kita-Ku, Osaka, 531-0072, Japan. jshen@anbas.co.jp
Horii
Yuko
Y
Fujisaki
Yoshiyuki
Y
Nagai
Katsuya
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001120:Arginine / Q000494:pharmacology* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects* / Q000502:physiology; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D008239:Lysine / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015213:Neuroimmunomodulation / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000294:innervation; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D001120:Arginine; D008239:Lysine